Value proposition

Mapping the universe of biology 🧬

NanoString Technologies, a Bruker Company, is a provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.

NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and gene expression detection. In 2019, the company launched the GeoMxTM Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMxTM Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMxTM Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched.

In 2024, NanoString Technologies has been acquired by Bruker Corporation, a leading global provider of scientific instruments and solutions. This strategic acquisition marks the beginning of a promising new chapter for NanoString and our valued customer.


Gene Expression, miRNA, CNV and Single Cell Analysis, Digital Genomics for Pathway-based Research, Multiplexed Molecular Diagnostic Development, General Purpose Reagents for Laboratory Use, and Translational Cancer Genomics and Cancer Research